RTTNews | Oct 29, 2021 08:36AM EDT

08:35 Friday, October 29, 2021 (RTTNews.com) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD).

In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six in the Montgomery-sberg Depression Rating Scale (MADRS) total score compared with placebo.

Patients treated with cariprazine at 1.5 mg/day achieved improved MADRS total score at week six compared to placebo. Patients treated with cariprazine at 3.0 mg/day demonstrated improvement in MADRS total score at week six over placebo but did not meet statistical significance.

In Study 3111-302-001, cariprazine demonstrated numerical improvement in depressive symptoms from baseline to week six in MADRS total score compared with placebo but did not meet its primary endpoint for either the 1.5 mg/day or 3.0 mg/day dose.

In a previously published Phase 2/3 registration-enabling study, RGH-MD-75, patients treated with cariprazine flexible doses of 2.0-4.5 mg/day in addition to ongoing antidepressant therapy (ADT) met the primary endpoint and achieved improved MADRS total scores at week eight compared to placebo.

Based on the positive results of studies 3111-301-001 and RGH-MD-75, and the totality of data reported, AbbVie intends to submit a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for the expanded use of cariprazine for the adjunctive treatment of MDD.

Read the original article on RTTNews ( https://www.rttnews.com/3237377/abbvie-says-cariprazine-met-primary-endpoint-in-phase-3-study-for-major-depressive-disorder.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved